RxDoctor Payments Data

Padmavathi Murakonda, MD

Geriatric Medicine · Bronx, NYNPI 1841389681

Payments from drug & device makers

$462in general payments, 2019–2025

Across 8 payments — averaging $57.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$266
  • Amarin Pharma, Inc.$103
  • Novartis$34
  • Johnson & Johnson$22
  • Aurinia Pharma U.S., Inc.$22
  • AbbVie$15

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462 in reported general payments places this provider in the 70th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$140,424
Medicare patients
367
Services billed
2,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$72,269
JanuviaSitagliptin Phosphate24$19,192
XareltoRivaroxaban35$15,017
SantylCollagenase Clostridium Hist.29$11,954
JardianceEmpagliflozin24$11,836
EntrestoSacubitril/Valsartan15$10,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,227
AbrysvoRsv Vacc, Pref A And Pref B/Pf17$5,349
Atorvastatin Calcium289$3,004
SavaysaEdoxaban Tosylate13$2,692
Diclofenac Sodium18$2,556
Mirtazapine111$2,517
Enoxaparin Sodium28$2,239
Methenamine Hippurate19$1,673
Albuterol Sulfate HfaAlbuterol Sulfate46$1,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$22$15,01735 claims
NovartisEntresto$34$10,19315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →